The involvement of
alarmin high-mobility group
nucleosome-
binding protein 1 (
HMGN1) in
non-small cell lung cancer (NSCLC) is unknown. To address the presence of
HMGN1 in the serum of different stages of NSCLC patients and healthy controls, we enrolled a consecutive sample of adult serum at diagnosis and correlated it with clinicopathologic outcomes. A total of 100 NSCLC patients and 23 healthy volunteers were enrolled from January 2012 through December 2013. Serum
HMGN1 levels were determined by
enzyme-linked
immunosorbent assay (ELISA). Additionally,
HMGN1 levels in 50 NSCLC patients with early-stage disease who received curative
pneumonectomy were correlated with survivals. Kaplan-Meier plots were used to analyze the data. The patients with NSCLC were characterized by significantly higher serum levels of
HMGN1 (0.4585 ± 0.0640 ng/ml) compared to those in healthy controls (0.3578 ± 0.0304 ng/ml). The serum
HMGN1 levels were 0.4027 ± 0.0271 ng/ml, 0.4604 ± 0.0328 ng/ml, 0.5408 ± 0.0459 ng/ml, and 0.4213 ± 0.0341 ng/ml in patients with TNM stages I, II, IV, and IV, respectively (p < 0.001). There were significant differences among four groups (p < 0.001). Additionally, a positive correlation between serum
HMGN1 and
tumor stage was found in local disease, while serum
HMGN1 level in metastatic NSCLC patients was significantly decreased. The Kaplan-Meier plots showed that patients with high serum
HMGN1 had a poorer overall survival (OS) after curative
pneumonectomy than those with low serum
HMGN1 (p = 0.019).
Inflammation triggered by
alarmins plays a role in NSCLC pathogenesis.
HMGN1 can serve as a useful clinical parameter for evaluating
disease progression and predicting the outcomes for early-stage patients with NSCLC undergoing
pneumonectomy.